Maarten van der Doelen

Chapter 4

Patients treated with radium-223 Informed consent obtained N = 124

Excluded from analysis n = 28

n = 28

Missing baseline questionnaire

Baseline HADS and CIS-F questionnaires available Included for analysis n = 96

Lost to follow-up n = 7

n = 3 n = 4

Refused follow-up questionnaire Missing follow-up questionnaire

Discontinuation of therapy End-of-therapy questionnaires available n = 15

n = 2 n = 4 n = 9

Discontinuation after first injection Discontinuation after second injection Discontinuation after third injection

Continuing radium-223 therapy Follow-up HADS and CIS-F questionnaires available after third radium-223 injection n = 74

Lost to follow-up n = 4

n = 1 n = 3

Refused follow-up questionnaire Missing follow-up questionnaire

Discontinuation of therapy End-of-therapy questionnaires available n = 13

n = 6 n = 7

Discontinuation after fourth injection Discontinuation after fifth injection

End-of-therapy HADS and CIS-F questionnaires available after sixth radium-223 injection n = 57

Number of injections received - grouped N = 96

Number of injections received N = 96

n = 2 n = 8 n = 9 n = 10 n = 8 n = 59

One injection Two injections Three injections Four injections Five injections Six injections

n = 19 n = 18 n = 59

One – two – three injections Four – five injections Six injections

Supplementary figure 2. Consort diagram patient enrollment regarding HADS and CIS-Fatigue questionnaires.

110